Skip to main content

Alzheimer’s Disease-Eisai (Mission AD2)

This study is a Phase 3 clinical trial investigating the efficacy of preventing the progression and symptoms associated with Early Alzheimer’s Disease (EAD), including mild cognitive impairment (MCI) due to Alzheimer’s disease.

Sponsor: Eisai Inc

Phase: 3

Indication: Mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD dementia

Age: 50 to 85 years of age

Category: Disease Modifying

For more information: https://clinicaltrials.gov/ct2/show/NCT02956486

Studies Currently Available At

Sign Up For This Study